NCT07179978View on ClinicalTrials.gov

Lorazepam and the Risk of Serious Adverse Events

CompletedOBSERVATIONAL
Enrollment

12,308

Participants

Timeline

Start Date

January 1, 2008

Primary Completion Date

September 1, 2024

Study Completion Date

October 1, 2024

Conditions
Chronic Kidney Disease (CKD)
Interventions
DRUG

Lorazepam

The primary exposure of interest will be oral lorazepam at a dose range of \>1-4 mg/day.

Trial Locations (1)

Unknown

London Health Sciences Centre Research Institute, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT07179978 - Lorazepam and the Risk of Serious Adverse Events | Biotech Hunter | Biotech Hunter